Earnings Releases·Nov 9, 2026, 7:00 AM ET

Turn Therapeutics — Third Quarter 2026 Earnings Summary

Net loss widened to $6.2 million ($0.21/share) for Q3 2026 from $1.9 million ($0.07/share) in the prior year period, driven by a $4.2 million non-cash loss from derivative liabilities; cash reserves increased to $10.4 million as of September 30, 2026.
Operational guidance updated to accelerate Phase 2a hidradenitis suppurativa enrollment to Q1 2027 and project Phase 2b atopic dermatitis topline results in Q1 2027, with current cash expected to fund operations through Q3 2027.
GX-03 Phase 2b trial enrollment is ongoing with 120–136 patients and zero dropouts; Stage 1 data showed 59.3% of patients achieved clear/almost clear skin at Week 4 versus 30.4% for vehicle, with 40.7% achieving EASI-100 at Week 8.
Strategic leadership expanded with the appointment of Dr. Robert R. Redfield as Chief Scientific Officer on September 9, 2026; the company remains pre-revenue with no capital return or M&A activity reported.